NXTC

NextCure, Inc. Common Stock

$3.38 -45.48%

Recent alerts on NXTC

All signals →

SEC filing NXTC Reports 55% ORR for SIM0505 in Gynecologic Cancers, 52.9% in Ovarian Cancer, Favorable Safety Profile in Phase 1 Trial

News NextCure (NXTC) Q2 Loss Widens 71%

SEC filing NXTC Reports $41.8M Cash, $55.8M Net Loss, SIM0505 Phase 1 Data Q2 2026, LNCB74 Dose Optimization H2 2026

Scanner Unusual volume (2.6x average)

Get push alerts for NXTC

Add it to your watchlist in the app and receive every signal the moment it fires.

Download for iOS

Download for iOS